157 related articles for article (PubMed ID: 22166404)
21. The Interplay Between Proteostasis Systems and Parkinson's Disease.
Lázaro DF; Outeiro TF
Adv Exp Med Biol; 2020; 1233():223-236. PubMed ID: 32274759
[TBL] [Abstract][Full Text] [Related]
22. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
23. Controlling the mass action of alpha-synuclein in Parkinson's disease.
Kim C; Lee SJ
J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
[TBL] [Abstract][Full Text] [Related]
24. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
Ulusoy A; Decressac M; Kirik D; Björklund A
Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
[TBL] [Abstract][Full Text] [Related]
25. Recurrent systemic infections with Streptococcus pneumoniae do not aggravate the course of experimental neurodegenerative diseases.
Ebert S; Goos M; Rollwagen L; Baake D; Zech WD; Esselmann H; Wiltfang J; Mollenhauer B; Schliebs R; Gerber J; Nau R
J Neurosci Res; 2010 Apr; 88(5):1124-36. PubMed ID: 19859962
[TBL] [Abstract][Full Text] [Related]
26. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
Li B; Zhang Y; Yuan Y; Chen N
Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
[TBL] [Abstract][Full Text] [Related]
27. Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells.
Garretti F; Agalliu D; Lindestam Arlehamn CS; Sette A; Sulzer D
Front Immunol; 2019; 10():303. PubMed ID: 30858851
[TBL] [Abstract][Full Text] [Related]
28. Synucleins and their relationship to Parkinson's disease.
von Bohlen Und Halbach O
Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
[TBL] [Abstract][Full Text] [Related]
29. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice--a model of familial Parkinson's disease.
Poon HF; Frasier M; Shreve N; Calabrese V; Wolozin B; Butterfield DA
Neurobiol Dis; 2005 Apr; 18(3):492-8. PubMed ID: 15755676
[TBL] [Abstract][Full Text] [Related]
31. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities.
Visanji NP; Lang AE; Kovacs GG
Transl Neurodegener; 2019; 8():28. PubMed ID: 31508228
[TBL] [Abstract][Full Text] [Related]
32. Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator.
Fernandes JT; Tenreiro S; Gameiro A; Chu V; Outeiro TF; Conde JP
Lab Chip; 2014 Oct; 14(20):3949-57. PubMed ID: 25167219
[TBL] [Abstract][Full Text] [Related]
33. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.
Gelders G; Baekelandt V; Van der Perren A
J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629
[TBL] [Abstract][Full Text] [Related]
34. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
Koo HJ; Choi MY; Im H
Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
[TBL] [Abstract][Full Text] [Related]
35. Mathematical approach to understand the kinetics of alpha-synuclein aggregation: relevance to Parkinson's disease.
Bharathi P; Nagabhushan P; Rao KS
Comput Biol Med; 2008 Oct; 38(10):1084-93. PubMed ID: 18823621
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
37. The expression of alpha-, beta-, and gamma-synucleins in olfactory mucosa from patients with and without neurodegenerative diseases.
Duda JE; Shah U; Arnold SE; Lee VM; Trojanowski JQ
Exp Neurol; 1999 Dec; 160(2):515-22. PubMed ID: 10619569
[TBL] [Abstract][Full Text] [Related]
38. Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease.
Visanji NP; Marras C; Kern DS; Al Dakheel A; Gao A; Liu LW; Lang AE; Hazrati LN
Neurology; 2015 Feb; 84(6):609-16. PubMed ID: 25589666
[TBL] [Abstract][Full Text] [Related]
39. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
[TBL] [Abstract][Full Text] [Related]
40. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
